Tag: Pipeline analysis

Mucopolysaccharidosis III (MPS III) (Sanfilippo Syndrome) Therapeutics Clinical Trials & Results

Mucopolysaccharidosis type III (MPS III), also known as Sanfilippo syndrome, is a progressive disorder that primarily affects brain and spinal cord (central nervous system). People with MPS III generally do not display features at birth, but they begin to show signs and symptoms of this disorder during early childhood. Affected children often initially have delayed…
Read more

Tosymra – Drug Insight and Forecast, 2018

Tosymra, previously known as DFN-02, an intranasal spray containing sumatriptan (10 mg) and a 5-HT1B/1D receptor agonist developed by Dr. Reddy’s Laboratories Limited and its subsidiary Promius Pharma, LLC, is approved by the USFDA in January, 2019 for the acute migraine.  Download the sample report at: https://www.pharmaproff.com/request-sample/1169 In a multicenter, double blinded, randomized, placebo-controlled study,…
Read more

Contepo – Drug Launch Insight, 2018

Contepo is a novel, potentially first-in-class intravenous investigational antibiotic with a broad spectrum of Gram-negative and Gram-positive activity, including activity against most contemporary multi-drug resistant (MDR) strains, such as ESBL-producing Enterobacteriaceae. In January 2019, Nabriva Therapeutics plc announced the acceptance of its new drug application (NDA) by the United States Food and Drug Administration (USFDA).…
Read more

Lemborexant – Drug Launch Insight, 2018

Lemborexant was discovered by Eisai Co. Ltd. in-house scientists. It is a novel investigational small molecule inhibiting orexin signaling by binding competitively to both orexin receptors subtypes (receptor 1 and 2). In January 2019, Eisai Co. Ltd. and Purdue Pharma L.P. submitted a new drug application (NDA) to the United States Food and Drug Administration…
Read more

Lumateperone– Drug Launch Insight, 2018

Lumateperone by Intra-Cellular Therapies Inc., has multiple mechanisms, such as that of a potent serotonin 5-HT2A receptor antagonist; a dopamine receptor phosphoprotein modulator (DPPM), acting as a presynaptic partial agonist and postsynaptic antagonist at dopamine D2 receptors, a dopamine D1 receptor-dependent indirect modulator of glutamate (both NDMA and AMPA), and a serotonin reuptake inhibitor.  Download…
Read more

Prader-Willi Syndrome – Epidemiology Insights (2016-2028)

Prader-Willi syndrome (PWS) is a complicated genetic condition which can affect various parts of the body. During infancy, this condition is identified by weak muscle tone (hypotonia), problems in feeding, poor growth, and delay in development. Download the sample report @ https://www.pharmaproff.com/request-sample/1163 It begins in childhood due to which the patients develop an insatiable appetite,…
Read more

Glaucoma – Epidemiology Insights (2016-2028)

Glaucoma can be described as a group of diseases characterized by cupping of the optic nerve head and visual-field damage. These diseases differ from each other in terms of their causes, risk factors, demographics, symptoms, duration, treatment, and prognosis. Download the sample report @ https://www.pharmaproff.com/request-sample/1159   The common identifiable features for all forms of glaucoma…
Read more

Immunoglobulin A (IgA) Nephropathy to Witness an Exponential Growth due to Positive Clinical Results in the Coming Years | Key Players are Mallinckrodt Pharmaceuticals, Pharmalink AB, Anthera Pharmaceuticals, Rigel Pharmaceuticals Inc., Retrophin, Omeros Corporation

According to a new research report “Immunoglobulin A (IgA) Nephropathy-Pipeline Analysis, Clinical Trials & Results, Patents, Designations, Collaborations, Patient Size, and Epidemiology Forecast to 2028” published by Pharma Proff, Immunoglobulin A (IgA) Nephropathy therapeutics currently exhibits a proliferating pipeline with 24 therapeutic candidates. Download the sample report @ https://www.pharmaproff.com/request-sample/1211 IgA Nephropathy is referred to being as the utmost…
Read more